Navigation Links
Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
Date:5/20/2008

Analysis Reveals Overall Survival Could be Extended if Patients Receive the

Most Effective Treatment Identified by ChemoFx

CHICAGO, May 20 /PRNewswire/ -- Precision Therapeutics Inc. announced today that the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlates with significantly longer overall survival (OS) in patients with primary ovarian cancer. Patients who received a treatment determined by ChemoFx to lead to the best tumor response had an overall survival 1.4 times longer than those receiving a treatment shown by ChemoFx to be non-responsive.

Despite the fact that all patients had the same type of tumor, 88 percent of patients exhibited varying degrees of response to different agents when evaluated by the cell-based test. The analysis also found that nearly two-thirds of patients' tumors were more responsive to a treatment identified by ChemoFx, than to the treatment they actually received. Based on these results, a mathematical model was created to estimate survival had patients been treated with a drug that ChemoFx identified as more likely to result in a greater tumor response. The analysis found that median OS could be extended as much as 23 to 38 months.

"These overall survival data demonstrate that the responsiveness to treatment established by this sensitivity assay in the laboratory setting, may in fact translate into meaningful clinical outcomes for patients," said Thomas J. Herzog, MD, director of gynecologic oncology at the Columbia University Medical Center and lead investigator of the study. "If these results are confirmed in current ongoing trials, this will be a significant step towards establishing individualized treatment strategies for patients who will require chemotherapy."

About the Study

Patients analyzed in the study had stage II-IV primary epithelial ovarian cancer that was tested by ChemoFx between 1997 an
'/>"/>

SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)... CREEK, Mich., Oct. 10 /- Diplomat Sp...ience has selected Diplomat,Specialty Pharmacy to ...ge,scale, national Therapy Optimization Study for ...o year TOP MS study, is to examine the benefits of...n compliance, adherence and,patient outcomes. Targ...
(Date:10/10/2008)...M, Mass., Oct. 10 /- Invern...ding provider of near-patient,diagnostics, monitor... with,Ban Ki-moon, the Secretary-General of the Un...ves of seventeen of the world,s leading,research-b...panies.,Inverness, together with senior officials ...
(Date:10/10/2008)...NTON, Calif., Oct. 10 /- TriReme Medi...thorized to affix the CE (Conformite,Europeenne) m... Coronary,Stent System, a unique main vessel stent...nary bifurcations., Representing the next generat...m has potential use in a quarter of the 2.2 millio...
(Date:10/9/2008)...Sight Day 2008 focuses on the need to protect the ...swire/ -- Of the 45 million people worldwide who,a...arters of them could,have avoided their blindness ...To view the Multimedia News Release, go to:, http:...e world,s leader in eye care products and equipmen...
Breaking Medicine Technology:Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life Threatening Diarrhoel Diseases 7925 1Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life Threatening Diarrhoel Diseases 7925 2Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life Threatening Diarrhoel Diseases 7925 3Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life Threatening Diarrhoel Diseases 7925 4Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life Threatening Diarrhoel Diseases 7925 5Majority of children vaccinated against hepatitis B not at increased risk of MS 26804 1Surgery May Not Help Most People With Narrowed Brain Artery 26799 1Surgery May Not Help Most People With Narrowed Brain Artery 26799 2Surgery May Not Help Most People With Narrowed Brain Artery 26799 3Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels 3158 1Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels 3158 2Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels 3158 3
...es Inhibited Tumor Growth By, ...e,s Antibodies that Selectively Inhibit VEGF Recep...-Selective Approaches - , - These Results Along wi...t , Advancing Peregrine,s Anti-VEGF Program toward...f., April 16, 2007,/PRNewswire-FirstCall/ -- Pereg...
...ELD, N.J., April 16, 2007 /PRNewswire-FirstCall/ -...o and in vitro,preclinical data presented in a pos...h (AACR) Annual Meeting show that ONCONASE,(ranpir...mall cell,lung cancer (NSCLC) and breast cancer ce...nd reduced lactate,levels by ranpirnase in human l...
Other Medicine Technology:Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 2Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 3Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 5Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of,Non-Small Cell Lung Cancer, Breast Cancer Cells 2Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of,Non-Small Cell Lung Cancer, Breast Cancer Cells 3
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
... in helping us grow from a hollow sphere of stem c... They found that in the first few days of life, ce...ive ectoderm from which embryonic tissues develop,... biochemist at the Medical College of Georgia. Pr...
...riott International claimed the complete elimina...nu throughout all its 2300// hotels. The company ...ar and had since phased out trans-fats; partially ...rteries, from its cookies, breads, salad dressings...
...ore dispensaries by 2010 to provide better healthc... said Thursday.// She said 365 dispensaries were ... would be set up soon to "enable the common men av...heir doorsteps". The chief minister said her gov...
...ce and cherries, plus drinking red wine daily coul..., says a new study.// Scientists have found melato... from age-related damage, said the online edition ...s a naturally-occurring hormone not only found in ...
Other Medicine News:Health News:Lipid Plays Big Role in Embryonic Development 2
The standard pH Testing Application for POLYGRAM NET® (PNET) works with the Bravo™ Catheter-Free pH Monitoring System, Digitrapper™ Catheter-Based pH Recorder, and the Synectics Digit
...The Esophageal Manometry Application for POLYGRAM ...multiparametric recorder to record and analyze pre...uring esophageal manometry procedures. The PNET so...e solid-state or water-perfused manometry catheter...
The Biofeedback Application for POLYGRAM NET™ (PNET) works with the Polygraf™ ID to display, record, and analyze pressure and EMG signals from the pelvic floor in an interactive graphic f
...The Bile Reflux Analysis for POLYGRAM NET® is ...This add-on allows medical professionals to upload... ambulatory bile reflux recorder. The primary diff...sorbance of a certain wavelength of light correspo...
Medicine Products: